Dr. Susan Branford - CML - Chronic Myeloid Leukemia
Department of Molecular Pathology,
Centre for Cancer Biology,
SA Pathology and the University of Adelaide,
Adelaide, Australia.
Centre for Cancer Biology,
SA Pathology and the University of Adelaide,
Adelaide, Australia.
ARTICLES
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
February 5, 2015, Journal Blood
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
June 24, 2014, Journal Blood
Chronic myelogenous leukemia: monitoring response to therapy
June 6, 2011, PubLMed
Mutational analysis in chronic myeloid leukemia: when and what to do?
March 18, 2011, PubLMed
Practical considerations for monitoring patients with chronic myeloid leukemia.
October 2010, Medicine JournalFeeds
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
July 1, 2006, Journal Blood
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
February 5, 2015, Journal Blood
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
June 24, 2014, Journal Blood
Chronic myelogenous leukemia: monitoring response to therapy
June 6, 2011, PubLMed
Mutational analysis in chronic myeloid leukemia: when and what to do?
March 18, 2011, PubLMed
Practical considerations for monitoring patients with chronic myeloid leukemia.
October 2010, Medicine JournalFeeds
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
July 1, 2006, Journal Blood
